B cell receptor signaling involves physical and functional association of FAK with Lyn and IgM  by Mlinaric-Rascan, Irena & Yamamoto, Tadashi
B cell receptor signaling involves physical and functional association of
FAK with Lyn and IgM
Irena Mlinaric-Rascana;b, Tadashi Yamamotoa;*
aDepartment of Oncology, Institute of Medical Science, University of Tokyo, Shirokanedai 4-6-1, Minato-ku, Tokyo 108-8639, Japan
bDepartment of Biochemistry and Molecular Biology, Institute Jozef Stefan, Jamova 39, SI-1000 Ljubljana, Slovenia
Received 12 March 2001; accepted 4 May 2001
First published online 15 May 2001
Edited by Julio Celis
Abstract B cell receptor (BCR) stimulation induces phosphor-
ylation of a number of proteins, leading to functional activation
of B lymphocytes. Focal adhesion kinase (FAK) is a non-receptor
protein tyrosine kinase, involved in a variety of signaling
pathways. In this study, we show that FAK is tyrosine-
phosphorylated and activated following BCR stimulation. We
also demonstrate constitutive association of FAK with the Src-
family kinase Lyn and with components of the BCR. Association
of Lyn with FAK which was not correlated with BCR-induced
activation of both kinases, appeared to be mediated via the
binding of Lyn to the COOH-terminal part of the FAK molecule.
Our results indicate that FAK is a component of the BCR
complex and that it participates in BCR signaling. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
B cell antigen receptor (BCR) is a molecular complex con-
sisting of a transmembrane immunoglobulin (Ig) chain, which
recognizes antigen, and Ig-K/Ig-L dimers, which function as
signal transducers [1]. The Src-family protein tyrosine kinase
Lyn is thought to be a key initiator of BCR signaling [2] by
virtue of its physical association with the receptor and its
immediate activation upon BCR cross-linking [3,4].
Focal adhesion kinase (FAK) is a 125-kDa non-receptor,
proline-rich protein tyrosine kinase [5^7]. It possesses a cen-
tral catalytic domain and large NH2- and COOH-terminal
non-catalytic regions devoid of Src homology (SH)2 and
SH3 sequences [5]. In addition, the COOH-terminal domain
contains a focal adhesion targeting sequence (FAT), which is
responsible for targeting FAK to focal contacts and is in-
volved in signaling-induced cytoskeletal rearrangement [8,9].
In some cell types, the COOH-terminal domain of p125FAK is
expressed autonomously as a 41-kDa protein termed focal
adhesion kinase (FAK)-related non-kinase (FRNK), repre-
senting a kinase-negative domain that functions as an endog-
enous regulator of FAK activity [10,11].
Activation of FAK involves autophosphorylation of Tyr-
397, which lies within a sequence motif representing a high-
a⁄nity binding site for the SH2 domain of Src-family protein
tyrosine kinases (PTKs) [10,12]. The formation of Src^FAK
complex leads to increased catalytic activity of FAK, and
phosphorylation of other tyrosine residues on FAK that re-
sults in creation of speci¢c docking sites for multiple proteins
[13]. FAK interacts with other signaling molecules through its
SH2-binding motifs or proline-rich regions. For instance, Fyn,
Src, Csk, the p85 subunit of phosphatidylinositide 3-kinase,
and GRB2 are known to associate with FAK through their
SH2 domains, whereas p130cas (Crk-associated substrate)
binds the proline-rich region of FAK through an SH3 do-
main. Other potential physiological substrates of FAK, such
as cytoskeletal proteins paxillin and tensin, bind via speci¢c
sequences [14]. FAK is tyrosine-phosphorylated in response to
distinct cellular stimuli including integrin-mediated cell adhe-
sion, mitogenic neuropeptides, bioactive lipids, polypeptide
growth factors, and bacterial toxins. FAK-mediated signal
transduction is implicated in embryonic development and in
the control of cell migration [15] proliferation, and apoptosis
[16,17].
Previous studies have shown FAK expression in lympho-
cytes [18,19], and its activation upon stimulation of L1-integ-
rin and TCR [20^23]. Here we investigate the role of FAK in
B lymphocytes and demonstrate that FAK was activated fol-
lowing the surface IgM cross-linking. We also show FAK
association to Src-family kinase Lyn and to components of
BCR. We postulate the role of FAK to be in linking early
BCR signaling events to cytoskeletal reorganization.
2. Materials and methods
2.1. Antibodies
F(abP)2 fragment of goat anti-mouse IgM was from Cappel (Dur-
ham, NC, USA). Goat anti-mouse IgM, and anti-Flag M2 antibodies
were from Sigma (St. Louis, MO, USA), and goat anti-mouse IgG
from Southern Biotech Ass. Inc. (Birmingham, AL, USA). Antibodies
speci¢c to N- or C-terminal FAK (A-17, C-20), and anti-p107 were
from Santa Cruz Biotech. Inc. (Santa Cruz, CA, USA). Rabbit poly-
clonal anti-FAK antibodies JF1 were described previously [15]. Bio-
tin-conjugated anti-phosphotyrosine MAb (4G10) and MAb to FAK
(2A7) were from Upstate Biotechnology Inc. (Lake Placid, NY,
USA). Mouse monoclonal anti-Lyn antibody (Lyn 8) was from
Wako Pure Chemicals (Osaka, Japan). HM79, a hamster monoclonal
antibody against mouse Ig-L was a kind gift of Dr. Kisaburo Nagata,
Tokyo Metropolitan Institute [24].
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2.2. Transient transfections
Fibroblast cell line 293T was cultured in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) with 10% FCS at 37‡C under 5% CO2. Cells
(1U105/10 cm dish) were plated overnight and transfected by the
calcium phosphate method with 8 Wg of plasmids expressing FAK
or FRNK, and then cultured for 48 h before harvesting. Cells were
lysed in 1 ml of TNE lysis bu¡er per 10 cm dish (1% NP-40, 50 mM
Tris, pH 8.0, 150 mM NaCl, 20 mM EDTA, 0.1 mM sodium ortho-
vanadate, 10 mM sodium £uoride, 10 Wg/ml aprotinin). To recover
Lyn immune complexes, 200 Wl of cell lysates was immunoprecipitated
with 2 Wg of anti-Lyn antibody and analyzed on sodium dodecyl sul-
fate^plyacrylamide gel electrophoresis (SDS^PAGE). The constructs
expressing mouse FAK and FRNK were a kind gift of Jiro Fujimoto
(IMSUT, University of Tokyo, Japan) and Dusko Ilic (University of
California, San Francisco, CA, USA) [25], respectively. In short, the
cDNA encoding mouse FAK was cloned into pME18S expression
vector, and the sequence of FRNK was tagged with the double hem-
agglutinin (HA) and cloned in-frame into expression vector pEGFP-
C1 (Clontech Laboratories, Palo Alto, CA, USA), to obtain green
£uorescent protein (GFP)-FRNK-HA tagged fusion protein.
2.3. Cell activation and immunoprecipitation
WEHI 231 cell line and J2-transformed murine B lymphocytes were
cultured in RPMI 1640 containing 10% FCS and 50 WM 2-ME, at
37‡C under 5% CO2. Surface IgM of WEHI 231 cells or immortalized
mouse cell lines (2U107 cells) was cross-linked with either 10 Wg of
goat anti-IgM (Sigma) or F(abP)2 fragment of anti-IgM (Cappel) at
37‡C for designated period (1 or 5 min). Activation was stopped by
addition of 1 ml of ice-cold TNE lysis bu¡er. Unstimulated cells were
¢rst lysed and thereafter the anti-IgM antibody was added in order to
normalize lysate composition. IgM immunoprecipitates were recov-
ered by incubating with protein G-Sepharose (Pharmacia Biotech
Inc.). To recover Ig-L, FAK, or Lyn immune complexes, the lysates
were ¢rst precleared with excess amount of protein G-Sepharose, then
incubated with anti-Ig-L, anti-FAK (2A7) or anti-Lyn antibodies,
respectively. Immune complexes were collected on protein G-Sephar-
ose beads. When FAK was immunoprecipitated by C-20 or N-17
antibodies the lysates were precleared with protein A-Sepharose,
which was used as well for complex capture. Upon intense washing
in ice-cold lysis bu¡er, pellets were resuspended in SDS sample bu¡er
(125 mM Tris^HCl, pH 6.8, 4% SDS, 20% glycerol, 200 mM DTT,
and 0.02% bromophenol blue) and boiled for 5 min.
2.4. Immunoblotting
Proteins in immunoprecipitates or lysates were separated on 7.5%
SDS^polyacrylamide gels followed by blotting to polyvinylidene di-
£uoride membranes (Millipore, Bedford, MA, USA). Membranes
were blocked in 5% BSA (Boehringer, Mannheim, Germany) in
TBS bu¡er (10 mM Tris, pH 7.4, 150 mM sodium chloride). For
anti-phosphotyrosine immunoblotting, the membranes were incubated
with 1 Wg/ml of biotinylated 4G10 antibody (Upstate Biotechnology
Inc.). Blots were further incubated with streptavidin-horseradish per-
oxidase (sa-HRPO). Reactive bands were visualized by the use of
enhanced chemiluminescence detection system (Du Pont). For immu-
nodetection of other antibodies, alkaline phosphatase (ALP)-conju-
gated anti-rabbit or anti-mouse antibodies were used (Promega, Mad-
ison, WI, USA) and visualized by the NBT/BCIP colorimetric
method. Donkey anti-goat IgG-ALP was detected by the Vista ECF
(Amersham Pharmacia Biotech) system. Membranes developed by
ECF reagent (Amersham Pharmacia Biotech) were submerged to
quantitation and scanning on a Storm phosphorimager (Molecular
Dynamics, Sunnyvale, CA, USA).
2.5. Immunoprecipitated FAK kinase assay
FAK was immunoprecipitated from cell lysates (corresponding to
5U106 cells/sample) with 2A7 MAb. Upon intense washing, each
pellet was resuspended in 20 Wl of kinase bu¡er (40 mM HEPES,
pH 7.4, 10 mM MgCl2, 3 mM MnCl2, 0.1 mM sodium orthovana-
date). The reaction was carried out at 37‡C for 10 min in the kinase
bu¡er including 0.25 WCi [Q-32P]ATP (NEN, Life Science Products),
and terminated by the addition of SDS sample bu¡er. The proteins
were resolved by SDS^PAGE (8%), and 32P-incorporated proteins
were analyzed after autoradiography or by densitometer scanning us-
ing phosphorimager BAStation-2500 (Fuji Film, Japan).
3. Results
3.1. FAK is tyrosine-phosphorylated and activated upon BCR
cross-linking of WEHI 231
Tyrosine kinase FAK has been implicated in the regulation
of signaling pathways that are relevant to growth, di¡erentia-
tion, and activation of cells. The function of FAK in B cells
was studied in WEHI 231 cells. Surface IgM was ligated with
intact anti-IgM antibody for 1 or 5 min and the tyrosine
phosphorylation level of proteins from whole cell extracts
was determined. We detected stimulation-dependent phos-
phorylation of numerous cellular proteins with maximal phos-
phorylation detected at 1 min (Fig. 1A), as reported previ-
ously. To examine the tyrosine phosphorylation levels of
FAK the kinase was immunoprecipitated from lysates of un-
stimulated or IgM-stimulated WEHI 231 cells. Anti-FAK
(JF1) immune complexes were analyzed by immunoblotting
for the presence of phosphoproteins. An increase in the level
of tyrosine phosphorylation of FAK was observed following
BCR cross-linking, with maximum phosphorylation at 1 min
that diminished by 5 min. Reprobing of the blot with anti-
Fig. 1. BCR signaling involves tyrosine phosphorylation and activa-
tion of FAK. A: WEHI 231 cells were stimulated with anti-IgM
antibody for the indicated time. Protein from whole cell lysates
(2U105 cells/lane) were fractionated on SDS^PAGE (7.5%), trans-
ferred to nitrocellulose ¢lters, and analyzed for the presence of tyro-
sine-phosphorylated proteins (IB: PY). Molecular size markers are
indicated. B: Anti-FAK (JF1) immunoprecipitates (IPs) prepared
from 2U107 unstimulated (0), and anti-IgM-stimulated (1 and
5 min) WEHI 231 cells. IPs were separated by SDS^PAGE (7.5%).
The blotted ¢lters were probed with anti-phosphotyrosine antibody
(upper panel, IB: PY). Phosphorylated FAK is indicated by an as-
terisk. To demonstrate that equal amounts of proteins were immu-
noprecipitated, the same ¢lters were reprobed with anti-FAK (JF1,
IB: FAK). C: In vitro kinase reaction. Precleared lysates were im-
munoprecipitated with anti-FAK (2A7) antibody. After intense
washing, the IPs were subjected to in vitro kinase reaction for 10
min in the kinase bu¡er including [Q-32P]ATP. Numbers below the
lanes indicate the fold increase in band intensity for a particular as-
say.
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FAK antibodies con¢rmed that equivalent amounts of pre-
cipitated proteins were loaded (Fig. 1B). These data suggest
that FAK is involved in BCR transduced signaling in WEHI
231 cells. Comparable results were obtained by immunopreci-
pitating FAK with either polyclonal (JF1) or monoclonal
(2A7) anti-FAK antibodies (data not shown). In addition,
anti-FAK blots (Fig. 1B, lower panel) reveal two immunore-
active bands having di¡erent relative mobility, suggesting that
FAK exists in multiple isoforms. This result is consistent with
data published for other cell lines; several splice variants of
FAK were isolated from neuronal tissues [26].
Since kinase activity and phosphotyrosine levels of FAK
are related, proteins immunoprecipitated with anti-FAK
(2A7) antibody from IgM-stimulated or non-stimulated
WEHI 231 cells were assayed for kinase activity. Levels of
FAK autophosphorylation were determined by the levels of
incorporation of 32P. Maximal autokinase activity was
reached after 1 min of BCR cross-linking, representing a 5-
to 10-fold average increase in kinase activity. FAK activation
diminished by 5 min of BCR stimulation, suggesting the in-
volvement of FAK in early BCR signaling (Fig. 1C).
3.2. FAK signaling complex involves Lyn
The above data clearly demonstrate the involvement of
FAK in early BCR signal transduction, having activation ki-
netics similar to those of the Src-family PTKs. Since activated
FAK interacts with Src-like kinases [8,12,13], we have hy-
pothesized that FAK interacts with Lyn during BCR signal-
ing.
To investigate the relationship of FAK with Lyn, we exam-
ined whether these proteins associated with each other. Ly-
sates of untreated or anti-IgM treated WEHI 231 cells were
incubated with either anti-Lyn or anti-FAK antibodies, and
the immune complexes were subjected to immunoblotting
with anti-phosphotyrosine antibody. The analyses of FAK
immunoprecipitates revealed activation-dependent induction
of several phosphoproteins, among which were the proteins
of apparent molecular mass of 125 and 50^60 kDa. When this
same blot was probed with anti-Lyn antibody, equimolar
amounts of Lyn and FAK proteins were detected regardless
of anti-IgM treatment (Fig. 2, left panel). Reciprocal results
were obtained by probing Lyn immunoprecipitates with anti-
phosphotyrosine antibody. Apart from the tyrosine-phosphor-
ylated p53/56 band the phosphotyrosine of an apparent mo-
lecular mass of 125 kDa was detected upon anti-IgM treat-
ment. Reprobing the same membrane with anti-FAK
antibodies revealed that this protein has the same mobility
as FAK protein. These data showed Lyn kinase to be con-
stitutively associated with FAK and associated FAK to be
tyrosine-phosphorylated 1 min after BCR stimulation. The
kinetics of FAK tyrosine phosphorylation appears similar to
those of Lyn (Fig. 2, right panel). Our ¢ndings strongly imply
that both molecules are engaged in very early events of BCR
signaling.
3.3. The carboxy-terminal part of FAK is su⁄cient for the
association with Lyn
Autophosphorylation of FAK Tyr-397 provides a direct
binding site for the SH2 domain of Src-family PTKs. Thus,
formation of a FAK^Src signaling complex is thought to be
dependent on phosphorylation of Tyr-397 and the activity of
both kinases [27]. Association of Lyn and FAK kinases in a
WEHI 231 cell line (Fig. 2), however, implies that the activity
of these kinases is not necessary for their interaction. To iden-
tify a sequence on FAK required for the constitutive associ-
ation with Lyn we checked whether the COOH-terminal part
of the FAK molecule is su⁄cient for interaction with Lyn.
FAK, or its COOH-terminal isoform FRNK, was overex-
pressed by transiently transfecting 293T cells with expression
plasmids carrying FAK or FRNK cDNAs. Expression of
FAK or FRNK proteins and their e¡ect on overall protein
phosphorylation levels were determined by immunoblotting
with anti-phosphotyrosine antibodies. Lysates from cells over-
expressing FAK, but not FRNK, revealed an overall increase
of tyrosine phosphorylation and extensive tyrosine phosphor-
ylation of polypeptide with a relative mobility of 125 kDa
(Fig. 3, lane 5). We next examined the possible interaction
between Lyn and FAK or Lyn and FRNK. Anti-phosphotyr-
osine immunoblotting of anti-Lyn immunoprecipitates (Fig. 3,
lanes 1^3) had identi¢ed the phosphoproteins of an approx-
imate molecular mass of 15 kDa that were, upon anti-FAK
blotting, identi¢ed as FAK proteins. An anti-FAK reactive
double band with relative mobility of 66 kDa was detected
in anti-Lyn immunoprecipitates of lysates overexpressing
FRNK.
The mobility of these bands corresponds to that of GFP-
FRNK-HA fusion protein. The identity of the fusion protein
was con¢rmed in separate experiments with anti-HA antibody
(data not shown). These results demonstrate co-immunopre-
cipitation of endogenous Lyn kinase with transiently ex-
pressed FAK and FRNK proteins in 293T cells and indicate
that the COOH-terminal part of the FAK molecule is su⁄-
cient for association with Lyn. Association of endogenous
Lyn and FAK kinases in 293T cells was observed when larger
Fig. 2. FAK constitutively associates with Lyn in WEHI 231 cells.
FAK (N-17, left panel) and Lyn (right panel) were immunoprecipi-
tated from lysates of unstimulated (0), and anti-IgM-stimulated (1
and 5 min) WEHI 231 cells (1U107 cells/assay). The immunopreci-
pitates were separated by SDS^PAGE (7.5%). To detect tyrosine-
phosphorylated proteins, the ¢lters were immunoblotted with anti-
phosphotyrosine antibody (IB: PY). Asterisks indicate apparent po-
sition of FAK, and the double arrowheads of Lyn migration. Mo-
lecular size markers are shown on the left side of the panel.
Amounts of immunoprecipitated FAK or Lyn were determined by
reprobing the same ¢lters with anti-FAK (IB: FAK) and anti-Lyn
(IB: Lyn) antibodies. The mobility of p53lyn appears to overlap
with the heavy chain of the precipitating antibody (H).
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amounts of lysates were used (data not shown). These ¢ndings
support constitutive association of Lyn and FAK in unstim-
ulated WEHI 231 cells, where both kinases are believed to be
inactive. However, we are unable to conclude, at this stage,
whether this interaction is due to the direct binding of Lyn to
FAK or FRNK, or due to binding of both kinases to an
intermediate molecule.
3.4. Evidence of FAK localization within proximity of the IgM
complex
To further our understanding of the underlying mechanism
of FAK^Lyn interaction, we examined FAK localization rel-
ative to other components of the BCR. WEHI 231 cells were
stimulated with anti-IgM antibody and lysed in TNE bu¡er.
The same amount of anti-IgM antibody used to stimulate cells
was added to the extracts of unstimulated cells in order to
normalize lysate composition. IgM complexes were recovered
by incubating lysates of stimulated or non-stimulated cells
with protein G-Sepharose. Western blotting of IgM immuno-
precipitates with anti-FAK antibodies revealed the presence of
a 125-kDa FAK immunoreactive band, demonstrating consti-
tutive association of FAK with the BCR complex (Fig. 4A,
lanes 1, 2). We have subsequently analyzed anti-Ig-L immu-
noprecipitates. WEHI 231 cells were stimulated with F(abP)2
fragment of anti-IgM antibody. Then, the lysates were pre-
cleared and immunoprecipitated with anti-Ig-L antibodies.
Fig. 4. FAK is constitutively complexed with BCR and is tyrosine-
phosphorylated after BCR cross-linking. A: WEHI 231 cells were
stimulated by cross-linking of surface IgM by anti-IgM antibody (1,
1 min), unstimulated (0) aliquots were treated with same amount of
antibody. The IgM immune complexes were recovered from lysates
by protein G-Sepharose (lanes 1, 2). Similarly, cells were stimulated
by F(abP)2 fragment of anti-IgM, and Ig-L immune complexes were
recovered from lysates of unstimulated (0) or stimulated (1) cells
(lanes 3, 4). Proteins in the immunoprecipitates and total cell lysates
(tcl) (lanes 5, 6) were separated by SDS^PAGE (7.5%), transferred
to nitrocellulose ¢lters, and immunostained with anti-FAK antibody
(IB: FAK). Arrow indicates the position of p125FAK. B: Lysates of
2U107 WEHI 231 cells were precleared with protein G-Sepharose
and immunoprecipitated with anti-IgM (IgM), anti-p107 (p107),
anti-Flag (Flag), or anti-IgG (IgG) antibodies. Lysate corresponding
to 5U105 cells was loaded as a control (tcl). C: J2-transformed
murine B lymphocyte cells were stimulated by cross-linking with the
F(abP)2 fragment of anti-IgM antibody for 1 and 5 min. The cell ly-
sates of unstimulated aliquots (0) were treated with the same
amount of antibody. Protein G-Sepharose precleared lysates (107
cells/assay) were immunoprecipitated with intact goat anti-IgM anti-
body. Immunoprecipitates were separated by SDS^PAGE (7.5%),
transferred to a nitrocellulose ¢lter, and immunostained with anti-
phosphotyrosine antibody (IB: PY; upper panel). The position of
apparent FAK migration is marked by asterisks, and of Lyn by
double arrows. The amount of FAK co-immunoprecipitated with
IgM was determined by reprobing the same membrane with anti-
FAK antibody (IB: FAK). The ¢lter was also probed by anti-Lyn
antibody (IB: Lyn). Arrow indicates p56lyn. p53lyn appears to over-
lap with the heavy chain of the precipitating antibody (H).
Fig. 3. Lyn associates with FAK and FRNK. 293T cells were trans-
fected with plasmids containing FAK or FRNK cDNAs and lysed
in TNE bu¡er (1U107 cells/ml) 48 h after transfection. Lyn was im-
munoprecipitated from 200 Wl of lysates of non-transfected cells (0;
lane 1), or cells overexpressing FAK (FAK; lane 2), or FRNK
(FRNK; lane 3). The immunoprecipitates and the total cell lysates
(tcl, 2U105 cells/lane, lanes 4^6) were subjected to SDS^PAGE.
Separated proteins were transferred to nitrocellulose ¢lters and im-
munostained. Upper panel is anti-phosphotyrosine (IB: PY) blot,
which was reprobed with anti-FAK (middle panel, IB: FAK) or
anti-Lyn (bottom panel, IB: Lyn) antibodies. Position of FAK is in-
dicated by arrow, and of FRNK by double arrow. Endogenous
FAK can be detected in tcl of control and FRNK transfected cells
(lanes 4 and 6). The mobility of p53lyn overlaps with the heavy
chain of the precipitating antibody (H).
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Analyses of anti-Ig-L immunoprecipitates revealed stimula-
tion-independent assembly of FAK with Ig-L of the BCR
complex. In addition to the 125-kDa FAK protein, a 110-
kDa polypeptide reactive with anti-FAK antibodies was also
detected in anti-Ig-L immunoprecipitates, the identity of
which was not evaluated (Fig. 4A, lanes 3, 4). In order to
rule out the non-speci¢c binding of FAK to IgM, lysates of
WEHI 231 cells were subjected to immunoprecipitation with
irrelevant mouse monoclonal antibodies such as anti-p107,
-Flag, or -mouse IgG. None of these control immunoprecipi-
tates contained FAK protein (Fig. 4B). Our data clearly dem-
onstrate the presence of FAK in anti-IgM or anti-Ig-L immu-
noprecipitates, suggesting that FAK is localized proximal to
the BCR. To con¢rm the notion of FAK association with Lyn
and components of BCR, we have assayed the J2-transformed
murine B cells. TNE lysates of unstimulated or F(abP)2-stimu-
lated cells were precleared, immunoprecipitated with anti-IgM
or anti-Ig-L antibodies, and assayed for the presence of com-
plexed phosphoproteins and amounts of co-immunoprecipi-
tated FAK and Lyn. Several anti-IgM-associated phospho-
proteins were detected in Western blots stained with anti-
phosphotyrosine antibodies. By reprobing the same blots
with anti-FAK and anti-Lyn antibodies, we revealed a consti-
tutive association of FAK and Lyn with the BCR complex
(Fig. 4C). Equivalent results were obtained by anti-Ig-L anti-
bodies (data not shown).
4. Discussion
PTKs play a substantial role in BCR signal transduction.
We examined involvement of the focal adhesion kinase in this
process. FAK is expressed and tyrosine-phosphorylated in
either primary B and T cells as well as transformed cell lines
[18,19]. It becomes tyrosine-phosphorylated upon L1-integrin
ligation of human B cells [20,21] and TCR cross-linking on
Jurkat T cell line and murine CD8+ cytotoxic cells [22,23].
In elaborating the role of FAK in BCR signaling events we
provide evidence that FAK becomes tyrosine-phosphorylated
and activated as a consequence of surface IgM cross-linking
on WEHI 231 cells and murine J2-transformed B lympho-
cytes. In vitro cross-linking of the BCR induces activation
of several proteins. Lyn and FAK become activated after
BCR stimulation with apparently similar kinetics. Both
FAK and Lyn kinases are associated since FAK was detected
in Lyn immunoprecipitates and Lyn was detected in FAK
immunoprecipitates. The interaction of FAK and Src kinases
is mediated via the phosphorylated Tyr-397 of FAK and the
SH2 domain of Src [12]. Phosphorylation of Tyr-397 on FAK
facilitates the formation of a FAK^Lyn signaling complex in
which both kinases are active. However, in our experiments,
interaction of FAK and Lyn kinases was detected in both
IgM-stimulated and non-stimulated samples, implying that
the activity of these kinases is not necessary for their interac-
tion, and thus indicating activation-independent association of
both kinases. Therefore, we proposed a new mode of Lyn^
FAK interaction and showed that the COOH-terminal part
of the FAK molecule, which corresponds to FRNK, is su⁄-
cient for interaction with Lyn. This novel ¢nding can be ex-
plained by the presence of several protein^protein interaction
sites located in the COOH-terminal part of FAK. There
are two proline-rich sequences, P712PKPSRPGYPSP and
P874PKKPPRPGAP, that bind SH3 domains of p130cas [28]
or Cas-related protein HEF1, Graf, and Cdc42 [29] and, thus,
represent a likely candidate for the interaction of FAK and
Lyn in an activation-independent manner. Perhaps binding of
Lyn and FAK through such an interaction is a prerequisite
for the immediate and optimal activation of both kinases after
receptor stimulation. Alternatively, interaction of FAK with
Lyn may be regulated by FRNK. FRNK is independently
expressed in many cell types and is an endogenous regulator
of FAK [9,10]. The mechanism by which FRNK regulates
FAK is unknown. The physiological relevance of the pro-
posed regulation is suggested by the ability of ectopicly ex-
pressed FRNK to block both cell spreading and tyrosine
phosphorylation of FAK and paxillin [30]. Src overexpression
can override these e¡ects of FRNK [30] by a mechanism that
is likely to involve Src-mediated sequestration of FRNK. The
mechanism of constitutive association of Lyn and FAK is at
this moment unclear, it may be mediated by direct interaction
or via interfacing binding proteins.
Lyn is implicated in a variety of biochemical events in-
volved in BCR signaling. First, Lyn constitutively associates
with the non-activated receptor through interaction of the N-
terminal part of Lyn kinase with the cytoplasmic domain of
the Ig-K chain [31]. Based on our ¢ndings and consistent with
our prediction, FAK was detected in the anti-IgM and anti-
Ig-L immunoprecipitable complexes. However, the molecular
mode of such interaction is not clear. Our ¢ndings demon-
strating constitutive association of Lyn with FAK and BCR-
mediated FAK activation are complementary with the role of
FAK-related proline-rich tyrosine kinase-2 (Pyk2) in T lym-
phocytes, where Pyk2 is constitutively associated with Fyn
[32]. Further analogy can be drawn from the activation of
FAK in T cell signaling induced by chemoattractant
RANTES and its constitutive association with ZAP-70 tyro-
sine kinase [33].
BCR-induced tyrosine phosphorylation and activation of
FAK as well as its constitutive association with Lyn and anti-
gen receptor components classify FAK kinase as a BCR sig-
naling component. Activation of FAK after ligation of integ-
rin and antigen receptors on B and T cells suggests that the
BCR as well as the TCR and integrins share pathways in
which FAK may serve as a linker and contribute to functional
cross-talk. The formation of signaling complex including
FAK and Lyn may contribute to cytoskeletal reorganization
in B lymphocytes by linking antigen receptor stimulation to
components of the cytoskeleton.
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